Transgene SA (EPA:TNG)

Market Cap	213.59M +129.9%
Revenue (ttm)	7.58M +16.6%
Net Income	-36.78M
EPS	-0.28
Shares Out	273.83M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,520
Average Volume	143,407
Open	0.7800
Previous Close	0.7800
Day's Range	0.7580 - 0.7800
52-Week Range	0.5300 - 1.5000
Beta	0.65
RSI	37.60
Earnings Date	Mar 24, 2026

About Transgene

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; TG6002, an oncolytic virus that is in Phase I/IIa clinical trial for the treatment of solid tumors, including gastroi...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1979
• Employees: 147
• Stock Exchange: Euronext Paris
• Ticker Symbol: TNG

Financial Performance

In 2024, Transgene's revenue was 6.35 million, a decrease of -19.58% compared to the previous year's 7.90 million. Losses were -33.97 million, 52.1% more than in 2023.